Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma

touchPODCAST

touchPANEL DISCUSSION for touchONCOLOGY

Listen to a panel of leading experts discuss the latest evidence and clinical implications of recently approved treatments for relapsed/refractory follicular lymphoma (R/R FL), the importance of shared decision-making in treatment selection in the era of BsAb and CAR T-cell therapies, and the key considerations for treatment sequencing.

The experts

• Dr Matthew Lunning, University of Nebraska, Omaha, NE, USA,
• Professor Charalambos Andreadis, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA,
• Dr Tara Graff, Mission Cancer and Blood, Des Moines, IA, USA.

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Bristol Myers Squibb and is jointly provided by USF Health and touchIME.

For further information visit: https://touchoncologyime.org/evolving-treatment-paradigm-relapsed-refractory-follicular-lymphoma